Live
- Sudanese army recaptures capital of Sinnar State in central Sudan
- Kishkindha Kaandam Review: Some movies prove not to compromise in having a good cinematic experience and this is one of them
- Son-rise: Hemant Soren grows taller as tribal leader, makes father proud
- ISL 2024-25: 10-man NorthEast United FC hold on to take three points vs Punjab FC
- BGT 2024-25: Jaiswal’s application, commitment to form a partnership was so impressive, says Gilchrist
- BGT 2024-25: Personally, I am very happy with my performance, says Harshit Rana
- Pakistan's Lahore remains world's most polluted city despite light drizzle
- Asha Nautiyal retains Kedarnath for BJP, to be back as MLA after 12 years
- India leads world in science, innovation research: Minister
- Flash flood in Indonesia's South Tapanuli claims two lives
India’s Natco Pharma sued in US
The Hyderabad based pharmaceutical major Natco Pharma Ltd on Friday said the company and others have been named as defendants in a case filed in the US.
Chennai: The Hyderabad based pharmaceutical major Natco Pharma Ltd on Friday said the company and others have been named as defendants in a case filed in the US.
In a regulatory filing Natco Pharma said, the company along with Celgene Corporation, Bristol Myers Squibb and Breckenridge Pharmaceutical Inc., have been named as defendants in an antitrust lawsuit in the US.
The suit was filed by Louisiana Health Service & Indemnity Company D/B/A Blue Cross and Blue Shield of Losisiana and HMO Louisiana Inc., regarding Pomalidomide (Pomalyst). Pomalidomide is a generic drug for cancer.
"Natco believes this matter is without merit. Breckenridge is the ANDA (abbreviated new drug application) holder and distribution partner for the generic product in the US," Natco said.
Meanwhile Natco Pharma's scrip that opened at Rs.917.75 on Friday went down and was changing hands at about Rs 882.
